Temodar [temozolomide] and Sutent [sunitinib] as therapy for patients with malignant melanoma, a phase I/II study.

Trial Profile

Temodar [temozolomide] and Sutent [sunitinib] as therapy for patients with malignant melanoma, a phase I/II study.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Sunitinib; Temozolomide
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2009 Actual patient number (7) added as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Planned end date changed from 1 Apr 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top